Abstract: The invention relates to a dispenser 20 for the spray delivery of a preparation 18. The dispenser comprises: a reservoir 22 suitable for containing the preparation 18, a mechanical pump 24, a load chamber 26, a nozzle 28 having a delivery axis, and a delivery cone 30 having an axis. The mechanical pump is able, whenever operated: to take a predetermined amount of preparation from the reservoir, to supply said amount of preparation to the load chamber upstream of the nozzle, and to create a delivery pressure in the load chamber. The nozzle is able to deliver said amount of preparation in the form of an aerosol spray 180. The dispenser according to the invention is characterized in that the delivery cone comprises, in the proximity of the nozzle, at least one through-hole 320 suitable for putting the inside of the delivery cone into communication with the surrounding environment.

Abstract: The present invention relates to a combination comprising HSV-1 and HSV-2 binding monoclonal antibodies or fragments thereof and antiviral agents, the pharmaceutical formulations comprising said combination, optionally together with an excipient pharmaceutically acceptable and its use in the prophylaxis and/or treatment of herpes virus infections, including genital herpes, HSV gingivostomatitis and recurrent herpes labialis, herpes simplex encephalitis (HSE), neonatal HSV, HSV disease in the immunocompromised host and HSV keratitis keratoconjunctivitis.

Abstract: The present invention is in the field of monoclonal antibodies suitable for passive immunotherapy of Herpes Simplex Virus infections and relates to human monoclonal antibodies or fragments of said antibodies, which bind and neutralize HSV-1 and HSV-2, and their use in the prophylaxis or treatment of HSV-1 or HSV-2-associated diseases.

Abstract: The present invention relates to a combination comprising HSV-1 and HSV-2 binding monoclonal antibodies or fragments thereof and antiviral agents, the pharmaceutical formulations comprising said combination, optionally together with an excipient pharmaceutically acceptable and its use in the prophylaxis and/or treatment of herpes virus infections, including genital herpes, HSV gingivostomatitis and recurrent herpes labialis, herpes simplex encephalitis (HSE), neonatal HSV, HSV disease in the immunocompromised host and HSV keratitis keratoconjunctivitis.

Abstract: The present invention is directed to a method to treat onychomycosis by topically administering a composition which contains hydroxypropyl chitosan as the sole active ingredient and, in particular, by administering a nail topical composition consisting essentially of: a) hydroxypropyl chitosan, b) water, c) at least a lower alkanol.

Abstract: The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.

Abstract: Method for the treatment of onychoschizia in a patient having onychoschizia. The method is performed by administering to the patient a topical composition including (a) at least one herb extract from the genus Equisetum, and (b) at least one water-soluble film forming agent which is a derivative of chitosan.

Abstract: A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, b) at least one cellulose ether in preferred amounts of 30-90% and c) at least one disintegrant in preferred amounts of 2-50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. According to a preferred embodiment, the matrix is used in amounts of about 5-60% and the active principle in amounts of about 2-70%, with respect to the weight of the formulation.

Abstract: Method for prevention and treatment of vaginal fungal infections by administering a formulation comprising ascorbic acid or a physiologically acceptable salt thereof to a patient in need of such prevention or treatment. The formulation is administered after completion of the standard treatment against bacterial, fungal or protozoarian infections.

Abstract: The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions.

Abstract: Chitosan-based nail formulations are useful to treat nail inflammatory diseases like psoriasis, atopic dermatitis and lichen planus. The chitosan is normally in the form of an amino-polysaccharide derivative, preferably water soluble, such as hydroxypropyl chitosan. The formulation may be a nail lacquer, a spray, a cream, an ointment, a gel, a lotion or a foam and may have a content in chitosan, chitosan derivative or a salt thereof from 0.1 to 25 wt. % with respect to the total weight of the formulation.

Abstract: The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, forming a dermal film after application onto the skin, useful for delivery of actives onto the skin surface and in the stratum corneum.

Abstract: A time-specific delayed/pulsatile release dosage form which comprises: a core comprising at least one active principle and at least one disintegrating agent; a sealing layer surrounding the core essentially consisting of one or more water soluble or water insoluble pH independent polymers; an outer coating essentially consisting of one or more hydrophilic pH independent polymers; wherein: the at least one disintegrating agent is present in amounts of 1-20% by weight and the at least one active principle is present in amounts of 1-80% by weight, with respect to the core; the sealing layer accounts for 0.1-10% by weight, with respect to the core; the outer coating accounts for 5-500% by weight, with respect to the core. These coated cores are capable of ensuring the immediate release of the active principle after a pre-defined lag time, independently of physiological pH variations occurring in the gastro-intestinal tract of mammals.

Abstract: Compositions for vaginal use comprising lupulus (Humulus lupulus) and an excipient base suitable for application in the vaginal and/or vulvar region, for the treatment of vaginal dryness (atrophic vaginitis) and of the disorders correlated thereto, pruritus, burning sensation, dryness, dyspareunia; they are also particularly useful for delaying and attenuating the changes in the physiological trophism of the vulvar and vaginal tissue and mucosa.

Abstract: A lubricating/detaching/fluidifying additive composition for organic polymers is described, comprising a saturated hydrocarbon having from 25 to 35 carbon atoms with at least three side substituents consisting of a methyl group, combined with at least one polysiloxane polymer having a molecular weight higher than 500,000. The use of this composition or single hydrocarbon component as lubricating/detaching/fluidifying additive for organic polymers, is also described, together with a polymeric composition containing additives, comprising an organic polymer and the additive composition. The use according to the present invention is particularly advantageous as it is universal (the same additive for all organic polymers, regardless of their formulation); it allows the use of high viscosity/high M.W. polymers (suitable for extrusion), also in injection moulding, and enables the additive to be applied externally to the polymer.

Abstract: The present invention relates to a composition comprising a) at least one antimycotic agent and b) at least one film forming agent wherein component b) is a derivative of chitosan selected from hydroxyalkylchitosans and carboxyalkylchitosans and its use as a nail varnish. The present invention is further directed to the use of a water soluble film forming agent selected from hydroxyalkylchitosans and carboxyalkylchitosans as an additive in a nail varnish.

Abstract: A pharmaceutical formulation for the oral administration of cyclosporin is described, which formulation is capable of providing substantially constant and foreseeable plasma levels of the active ingredient. The formulation has the following quali-quantitative composition by weight: (a) cyclosporin in the amount of from about 8 to about 12% of the total weight; (b) ethanol in the amount of from about 12 to about 18% of the total weight; (c) a polyoxyethylene/polyoxypropylene block copolymer in the amount of from about 8 to about 12% of the total weight; (d) water in the amount of from about 4 to about 6% of the total weight; (e) a solubilizer having an HLB from 13 to 15 in the amount of from about 28 to about 40% of the total weight; (f) an ester of a C1-C6 alkyl alcohol and a C14-C18 saturated fatty acid in the amount of from about 20 to about 30% of the total weight.

Abstract: Disclosed are compounds of formula (A) ##STR1## wherein X, R.sub.1 and Y are as defined by the specification. The compounds are useful as antiandrogenic agents.